Advert - Theramex HQ UK Ltd – Case/0303/09/24

For failing to provide accurate and complete prescribing information, failing to promptly update prescribing information following changes to the summaries of product characteristics, not disclosing the details of two non-interventional studies in the appropriate manner, and the quality of relevant process documentation, Theramex was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 4.7 - Failing to publish the summary details and results of non-interventional studies of marketed medicines

Clause 5.1 - Failing to maintain high standards

Clause 8.3 - Failing to certify protocols relating to non-interventional studies

Clause 12.1 - Failing to provide accurate and up-to-date prescribing information